Lilly makes $3.8 billion vaccine bet to get back into infectious disease

Eli Lilly and Company (NYSE: LLY) is making a major push back into vaccines, signing deals worth up to 3.8 billion dollars to acquire three specialist developers focused on viral and bacterial infections.

Deal overview

Eli Lilly is buying Curevo, LimmaTech Biologics, and The Vaccine Company in a set of acquisitions aimed at rebuilding its presence in infectious disease.

These deals come as Eli Lilly continues an aggressive acquisition streak, adding new platforms and pipelines on top of its fast‑growing obesity and diabetes franchise.

Together, the three transactions are structured with upfront payments plus milestones tied to clinical, regulatory, and commercial progress, bringing the total potential value to about 3.8 billion dollars.

The focus is on vaccines for shingles and hard‑to‑treat bacterial infections, including Staphylococcus aureus, which is known for causing serious hospital and community‑acquired infections.

What Eli Lilly is buying

• Curevo: Eli Lilly is paying up to 1.5 billion dollars, split between an upfront payment and milestones, to acquire this shingles vaccine developer. Curevo’s work targets a large and aging population where shingles risk rises with age.
• LimmaTech Biologics: This deal could be worth up to 780 million dollars in upfront, clinical, and regulatory milestone payments. LimmaTech brings vaccine candidates against bacterial pathogens, led by a phase 1 vaccine program for Staphylococcus aureus.
• The Vaccine Company: Potentially the most expensive of the three, this acquisition is valued at up to 1.55 billion dollars across upfront, clinical, and commercial milestone payments. The company develops vaccines aimed at viral and bacterial threats, expanding Eli Lilly’s footprint across multiple infectious disease targets.

These transactions give Eli Lilly a diversified early‑ and mid‑stage vaccine pipeline, without depending on a single product to carry the entire strategy.

Why this matters for investors in LLY

For investors, Eli Lilly’s move signals a desire to build a second growth engine alongside its headline obesity and diabetes franchises.

Vaccines can create high‑margin, recurring revenue streams if products succeed and gain strong adoption, especially in large indications like shingles and major bacterial infections.

The 3.8 billion dollar price tag is spread over time through milestones, which helps manage risk: Eli Lilly pays most of the money only if the science delivers.

At the same time, the company is taking on typical biotech risks—clinical trial failures, regulatory uncertainty, and competition from other vaccine players—in exchange for the chance at long‑term growth.